A000100 Stock Overview
Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for A000100 from our risk checks.
Yuhan Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩70,300.00 |
| 52 Week High | ₩84,190.48 |
| 52 Week Low | ₩52,285.71 |
| Beta | 0.46 |
| 1 Month Change | -6.39% |
| 3 Month Change | 17.76% |
| 1 Year Change | 31.81% |
| 3 Year Change | 21.46% |
| 5 Year Change | 81.62% |
| Change since IPO | 5,991.20% |
Recent News & Updates
Recent updates
Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce
Mar 11
Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet
May 01Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?
Apr 16Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)
Mar 15Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Feb 25Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?
Feb 10
Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?
Jan 28The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More
Jan 13Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?
Dec 31Estimating The Fair Value Of Yuhan Corporation (KRX:000100)
Dec 18Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?
Dec 05Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Nov 20Shareholder Returns
| A000100 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 1.6% | -5.0% | -4.3% |
| 1Y | 31.8% | -1.4% | -1.0% |
Return vs Industry: A000100 exceeded the KR Pharmaceuticals industry which returned -1.4% over the past year.
Return vs Market: A000100 exceeded the KR Market which returned -1% over the past year.
Price Volatility
| A000100 volatility | |
|---|---|
| A000100 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A000100 has not had significant price volatility in the past 3 months.
Volatility Over Time: A000100's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 1,999 | Wook-Je Cho | www.yuhan.co.kr |
Yuhan Corporation, a pharmaceutical company, engages in the research, development, and production of active pharmaceutical products and intermediates in South Korea and internationally. It offers antivirals, antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds; and Revanex, an acid pump antagonist for the treatment of peptic ulcers and gastritis-related mucosal injury. The company also provides ETC products, such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory and allergy, and neuro systems, as well as anti-infective, anti-cancer, and hormone and other products; and analgesics, anti-rheumatics, and anesthetics.
Yuhan Corporation Fundamentals Summary
| A000100 fundamental statistics | |
|---|---|
| Market cap | ₩5.11t |
| Earnings (TTM) | ₩136.09b |
| Revenue (TTM) | ₩1.86t |
38.6x
P/E Ratio2.8x
P/S RatioIs A000100 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A000100 income statement (TTM) | |
|---|---|
| Revenue | ₩1.86t |
| Cost of Revenue | ₩1.29t |
| Gross Profit | ₩564.51b |
| Other Expenses | ₩428.42b |
| Earnings | ₩136.09b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82k |
| Gross Margin | 30.37% |
| Net Profit Margin | 7.32% |
| Debt/Equity Ratio | 10.8% |
How did A000100 perform over the long term?
See historical performance and comparison